Table 1. Dominant lethal assay (DLA) after males were treated with Zidovudine or Nevirapine for four weeks.
| Drug | Dose (mg/kg) | Sample size (n) | aPregnant (n) | DLA Implants (n) | ||||
| cSize | Dead | Resorbed | ||||||
| None | None | 6 | 1 | 8.0 | 0 | 0 | ||
| EMS | 480 | 6 | b0/1 | - | - | - | ||
| ZDV | 10 | 6 | - | - | - | - | ||
| 100 | 6 | 3 | 8.3 | 0 | 0 | |||
| 250 | 6 | - | - | - | - | |||
| NVP | 5 | 6 | 3 | 6.0 | 0 | 0 | ||
| 50 | 6 | b0/1 | - | - | - | |||
| 150 | 6 | b1/2 | 7.0 | 0 | 0 | |||
DLA simulates when the “father-only” is ARV treated.
EMS = Ethylmethylsulfonate (one-time dose); ZDV = Zidovudine; NVP = Nevirapine.
a
Number of pregnancies observed after 1∶1 mating.
b
Number of pregnancies before/after adding dams with heavy arterial linings to the pregnancy count. Dams with heavy arterial lining of the uterus and/or uterine fluids indicate fertile mating had occurred but was aborted early.
c
Number of implants per pregnant dam or the average from all pregnant dams in the group.
Statistical analysis could not be performed because of several missing values.